328 related articles for article (PubMed ID: 18378539)
1. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
3. Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Ying JE; Zhu LM; Liu BX
World J Gastroenterol; 2012 Feb; 18(8):736-45. PubMed ID: 22371633
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
5. Her signaling in pancreatic cancer.
Burtness B
Expert Opin Biol Ther; 2007 Jun; 7(6):823-9. PubMed ID: 17555368
[TBL] [Abstract][Full Text] [Related]
6. [Molecular-based treatment concepts in advanced pancreatic cancer].
Boeck S; Moosmann N; Stemmler HJ; Heinemann V
Dtsch Med Wochenschr; 2007 Apr; 132(15):818-22. PubMed ID: 17427093
[No Abstract] [Full Text] [Related]
7. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Saif MW
JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
[TBL] [Abstract][Full Text] [Related]
8. Recent updates on the role of chemotherapy in pancreatic cancer.
Burris HA
Semin Oncol; 2005 Aug; 32(4 Suppl 6):S1-3. PubMed ID: 16143160
[TBL] [Abstract][Full Text] [Related]
9. Promising newer molecular-targeted therapies in head and neck cancer.
Wang LX; Agulnik M
Drugs; 2008; 68(12):1609-19. PubMed ID: 18681486
[TBL] [Abstract][Full Text] [Related]
10. New directions in the management of advanced pancreatic cancer: a review.
Rocha-Lima CM
Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
[TBL] [Abstract][Full Text] [Related]
11. Molecular therapy of pancreatic cancer.
Plentz RR; Manns MP; Greten TF
Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced pancreatic cancer.
Ducreux M; Boige V; Malka D
Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349
[TBL] [Abstract][Full Text] [Related]
15. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
[TBL] [Abstract][Full Text] [Related]
17. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
18. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Horn L; Sandler AB
Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
20. Palliative chemotherapy for pancreatic malignancies.
Mehta SP
Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
